

Edgar Filing: PHARMION CORP - Form SC 13D

PHARMION CORP
Form SC 13D
May 15, 2006

CUSIP No. 74955W 30 7

Page 1 of 10 Pages

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D
(Rule 13d-101)

UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No.)1

Pharmion Corporation

(Name of Issuer)

Common Stock, \$.001 par value

(Title of Class of Securities)

71715B 40 9

(CUSIP Number)

Domain Associates, L.L.C.
One Palmer Square
Princeton, NJ 08542
Attn: Kathleen K. Schoemaker
Tel. (609) 683-5656

Ropes & Gray LLP
45 Rockefeller Plaza
New York, New York 10111
Attn: John C. MacMurray, Esq.
Tel. (212) 841-5700

(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)

May 4, 2006

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box [].

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

1The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act. (however, see the Notes).

Edgar Filing: PHARMION CORP - Form SC 13D

CUSIP No. 74955W 30 7

Page 2 of 10 Pages

1)	Name of Reporting Persons S.S. or I.R.S. Identification No. of Above Persons	Domain Partners VI, L.P.
	EIN No.:	

2)	Check the Appropriate Box if a Member of a Group*	(a) <input checked="" type="checkbox"/> (b) <input type="checkbox"/>

3)	SEC Use Only	

4)	Source of Funds	WC

5)	Check if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e)	<input type="checkbox"/>

6)	Citizenship or Place of Organization	Delaware

Number of Shares Beneficially Owned by Each Reporting Person With	7) Sole Voting Power	989,400
	8) Shared Voting Power	-0-
	9) Sole Disposi- tive Power	989,400
	10) Shared Dis- positive Power	-0-

11)	Aggregate Amount Beneficially Owned by Each Reporting Person	989,400

12)	Check if the Aggregate Amount in Row (11) Excludes Certain Shares	

13)	Percent of Class Represented by Amount in Row (11)	3.1%

14)	Type of Reporting Person	PN

CUSIP No. 74955W 30 7

Page 3 of 10 Pages

1)	Name of Reporting Persons S.S. or I.R.S. Identification No. of Above Persons	DP VI Associates, L.P.
----	--	------------------------

Edgar Filing: PHARMION CORP - Form SC 13D

EIN No.:

2)	Check the Appropriate Box if a Member of a Group*	(a) [x] (b) []

3)	SEC Use Only	

4)	Source of Funds	WC

5)	Check if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e)	[]

6)	Citizenship or Place of Organization	Delaware

Number of Shares Beneficially Owned by Each Reporting Person With	7) Sole Voting Power	10,600

	8) Shared Voting Power	-0-

	9) Sole Disposi- tive Power	10,600

	10) Shared Dis- positive Power	-0-

11)	Aggregate Amount Beneficially Owned by Each Reporting Person	10,600

12)	Check if the Aggregate Amount in Row (11) Excludes Certain Shares	

13)	Percent of Class Represented by Amount in Row (11)	Less than 0.1%

14)	Type of Reporting Person	PN

CUSIP No. 74955W 30 7

Page 4 of 10 Pages

1)	Name of Reporting Persons S.S. or I.R.S. Identification No. of Above Persons	Domain Partners IV, L.P.
----	--	--------------------------

EIN No.:

2)	Check the Appropriate Box if a Member of a Group*	(a) [x] (b) []

3)	SEC Use Only	

Edgar Filing: PHARMION CORP - Form SC 13D

4)	Source of Funds	Not Applicable
5)	Check if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e)	[]
6)	Citizenship or Place of Organization	Delaware
Number of Shares Beneficially Owned by Each Reporting Person With	7) Sole Voting Power	800,708
	8) Shared Voting Power	-0-
	9) Sole Dispositive Power	800,708
	10) Shared Dispositive Power	-0-
11)	Aggregate Amount Beneficially Owned by Each Reporting Person	800,708
12)	Check if the Aggregate Amount in Row (11) Excludes Certain Shares	
13)	Percent of Class Represented by Amount in Row (11)	2.5%
14)	Type of Reporting Person	PN

CUSIP No. 74955W 30 7

Page 5 of 10 Pages

1)	Name of Reporting Persons S.S. or I.R.S. Identification No. of Above Persons EIN No.:	DP IV Associates, L.P.
2)	Check the Appropriate Box if a Member of a Group*	(a) [x] (b) []
3)	SEC Use Only	
4)	Source of Funds	Not Applicable
5)	Check if Disclosure of Legal Proceedings is Required Pursuant to	[]

Edgar Filing: PHARMION CORP - Form SC 13D

Items 2(d) or 2(e)		
6)	Citizenship or Place of Organization	Delaware
7)	Sole Voting Power	9,155
8)	Shared Voting Power	-0-
9)	Sole Dispositive Power	9,155
10)	Shared Dispositive Power	-0-
11)	Aggregate Amount Beneficially Owned by Each Reporting Person	9,155
12)	Check if the Aggregate Amount in Row (11) Excludes Certain Shares	
13)	Percent of Class Represented by Amount in Row (11)	Less than 0.1%
14)	Type of Reporting Person	PN

CUSIP No. 74955W 30 7

Page 6 of 10 Pages

Schedule 13D

Item 1. Security and Issuer.

This statement on Schedule 13D relates to the Common Stock, \$.001 par value per share (the "Common Stock"), of Pharmion Corporation, a Delaware corporation ("Pharmion" or the "Issuer"). The Issuer's principal executive office is located at 2525 28th Street, Boulder, Colorado 80301.

Item 2. Identity and Background.

(a) This Schedule 13D is being filed on behalf of each of the following persons pursuant to Rule 13d-1(k) of Regulation D-G under the Securities Exchange Act of 1934, as amended (the "Exchange Act"): Domain Partners VI, L.P., a Delaware limited partnership ("DP VI"), DP VI Associates, L.P., a Delaware limited partnership ("DP VI A"), Domain Partners IV, L.P., a Delaware limited partnership ("DP IV"), and DP IV Associates, L.P., a Delaware limited partnership ("DP IV A") (collectively, the "Reporting Persons"). The Reporting Persons are making this single, joint filing because they may be deemed to constitute a "group" within the meaning of Section 13(d)(3) of the Exchange Act.

Edgar Filing: PHARMION CORP - Form SC 13D

The agreement among the Reporting Persons to file as a group (the "Joint Filing Agreement") is attached hereto as Exhibit A.

(b)-(c) The principal business of each of the Reporting Persons is that of a private investment partnership. The sole general partner of DP VI and DP VI A is One Palmer Square Associates VI, L.L.C., a Delaware limited liability company ("OPSA VI"), and the sole general partner of DP IV and DP IV A is One Palmer Square Associates IV, L.L.C., a Delaware limited liability company ("OPSA IV"). The principal business of OPSA VI is that of acting as the general partner of DP VI and DP VI A. James C. Blair, Brian H. Dovey, Jesse I. Treu, Kathleen K. Schoemaker, Robert J. More and Nicole Vitullo are the managing members of OPSA VI. The principal business of OPSA IV is that of acting as the general partner of DP IV and DP IV A. James C. Blair, Brian H. Dovey, Jesse I. Treu and Kathleen K. Schoemaker are the managing members of OPSA IV.

The principal address of each of the entities and individuals named in this Item 2 is c/o Domain Associates, L.L.C., One Palmer Square, Princeton, New Jersey 08542.

(d)-(e) During the last five years, none of the Reporting Persons or individuals named in this Item 2 has (i) has been convicted in any criminal proceeding (excluding traffic violations or similar misdemeanors); or (ii) been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction resulting in his being subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

(f) Each of the individuals named in this Item 2 is a citizen of the United States.

Item 3. Source and Amount of Funds or Other Consideration.

Between May 1, 2006 and May 4, 2006, DP VI and DP VI A purchased an aggregate 1,000,000 shares of Common Stock in open market transactions, at an average price of \$19.10 per share. The source of funds for such purchases was the working capital of DP VI and DP VI A, respectively.

Item 4. Purpose of Transaction.

DP VI and DP VI A purchased Common Stock of the Issuer for investment purposes. James C. Blair is a member of the Issuer's Board of Directors, but except as otherwise described in this statement, the Reporting Persons do not have any present plans or proposals that relate to or would result in: (i) the acquisition by any person of additional securities of the Issuer, or the disposition of securities of the Issuer; (ii) an extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries; (iii) a sale or transfer of a material amount of assets of the Issuer or any of its subsidiaries; (iv) any change in the

present board of directors or management of the Issuer, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board; (v) any material change in the present capitalization or dividend policy of the Issuer; (vi) any other material change in the Issur's

Edgar Filing: PHARMION CORP - Form SC 13D

business or corporate structure; (vii) changes in the Issuer's charter, by-laws or instruments corresponding thereto or other actions which may impede the acquisition of control of the Issuer by any person; (viii) causing a class of securities of the Issuer to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association; (ix) a class of equity securities of the Issuer becoming eligible for termination of registration pursuant to Section 12(g) (4) of the Exchange Act; or (x) any action similar to any of those enumerated above.

Item 5. Interest in Securities of the Issuer.

The information below is based on a total of 32,042,298 shares of Common Stock outstanding as of May 5, 2006, as reported in the Issuer's report on Form 10-Q filed with the Securities and Exchange Commission on May 10, 2006.

(a) DP VI directly beneficially owns 989,400 shares of Common Stock, or approximately 3.1% of the Common Stock outstanding. DP VI A directly beneficially owns 10,600 shares of Common Stock, or less than 0.1% of the Common Stock outstanding. OPSA VI, as the general partner of DP VI and DP VI A, may be deemed to indirectly beneficially own the securities owned by DP VI and DP VI A. DP IV directly beneficially owns 800,708 shares of Common Stock, or approximately 2.5% of the Common Stock outstanding. DP IV A directly beneficially owns 9,155 shares of Common Stock, or less than 0.1% of the Common Stock outstanding. OPSA IV, as the general partner of DP IV and DP IV A, may be deemed to indirectly beneficially own the securities owned by DP IV and DP IV A.

Managing Members of OPSA VI and OPSA IV

(i) James C. Blair directly beneficially owns 25,066 shares of Common Stock and indirectly beneficially owns through a family limited partnership 1,206 shares of Common Stock, or, in the aggregate, less than 0.1% of the Common Stock outstanding.

(ii) Brian H. Dovey owns no Common Stock.

(iii) Jesse I. Treu directly beneficially owns 5,919 shares of Common Stock and indirectly beneficially owns through a family limited partnership 8,578 shares of Common Stock, or in the aggregate less than 0.1% of the Common Stock outstanding.

(iv) Kathleen K. Schoemaker directly beneficially owns 1,516 shares of Common Stock, or less than 0.1% of the Common Stock outstanding.

(v) Robert J. More directly beneficially owns 2,209 shares of Common Stock, or less than 0.1% of the Common Stock outstanding.

(vi) Nicole Vitullo owns no Common Stock.

(b) The managing members of OPSA VI and OPSA IV may be deemed to share the power to vote or direct the voting of and to dispose or direct the disposition of the securities of the Issuer that are beneficially owned by DP VI and DP VI A and by DP IV and DP IV A, respectively. Each of the managing members of OPSA VI and OPSA IV disclaims beneficial ownership of all securities other than those he or she owns directly, if any, or by virtue of his or her indirect pro rata interest, as a managing member of OPSA VI and/or OPSA IV, in the securities owned by DP VI and DP VI A and/or by DP IV and DP IV A.

(c) Except as described in this statement, none of the Reporting Persons has effected any transactions in the Common Stock in the 60 days prior to the date

Edgar Filing: PHARMION CORP - Form SC 13D

of this statement.

CUSIP No. 74955W 30 7

Page 8 of 10 Pages

(d) Except as described in this statement, no person has the power to direct the receipt of dividends on or the proceeds of sales of, the shares of Common Stock owned by the Reporting Persons.

(e) Not applicable.

Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.

Not Applicable.

Item 7. Material to be Filed as Exhibits.

Not Applicable.

CUSIP No. 74955W 30 7

Page 9 of 10 Pages

SIGNATURES

After reasonable inquiry and to the best of their knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

Dated: May 10, 2006

DOMAIN PARTNERS VI, L.P.
By: One Palmer Square Associates VI,
L.L.C., General Partner

By /s/ Kathleen K. Schoemaker

Managing Member

DP VI ASSOCIATES, L.P.
By: One Palmer Square Associates VI,
L.L.C., General Partner

By /s/ Kathleen K. Schoemaker

Managing Member

DOMAIN PARTNERS IV, L.P.
By: One Palmer Square Associates IV,
L.L.C., General Partner

Edgar Filing: PHARMION CORP - Form SC 13D

By /s/ Kathleen K. Schoemaker

Managing Member

DP IV ASSOCIATES, L.P.

By: One Palmer Square Associates IV,
L.L.C., General Partner

By /s/ Kathleen K. Schoemaker

Managing Member

CUSIP No. 74955W 30 7

Page 10 of 10 Pages

EXHIBIT A

AGREEMENT REGARDING THE JOINT FILING OF
SCHEDULE 13D

The undersigned hereby agree that the statement on Schedule 13D to which this Agreement is annexed as Exhibit A is filed on behalf of each of them in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended.

Dated: May 10, 2006

DOMAIN PARTNERS VI, L.P.

By: One Palmer Square Associates VI,
L.L.C., General Partner

By /s/ Kathleen K. Schoemaker

Managing Member

DP VI ASSOCIATES, L.P.

By: One Palmer Square Associates VI,
L.L.C., General Partner

By /s/ Kathleen K. Schoemaker

Managing Member

DOMAIN PARTNERS IV, L.P.

By: One Palmer Square Associates IV,
L.L.C., General Partner

By /s/ Kathleen K. Schoemaker

Managing Member

DP IV ASSOCIATES, L.P.

By: One Palmer Square Associates IV,

Edgar Filing: PHARMION CORP - Form SC 13D

L.L.C., General Partner

By /s/ Kathleen K. Schoemaker

Managing Member